COCIR High Level Contribution
To the Proposal for Medical Device Regulation
Revision of Directive 93/42/EEC on Medical Devices

Introduction
COCIR, the voice of European manufacturers of medical diagnostic and imaging, electromedical and healthcare ICT industries, welcomes the revision of the EU Medical Devices Directive (MDD) and its replacement with a new Medical Devices Regulation (MDR). The new Regulation should build on the many merits of the existing regulatory approach while remaining robust, transparent and adaptable to scientific and technological progress. The primary objective of the revision process must be to achieve smart and efficient regulation delivering patient safety, high quality and rapid access to innovative medical technology.

Since the very beginning of the revision process in 2008, COCIR has continually shared detailed input on all aspects of the proposed Regulation of relevance to our sector. This document is a high level contribution to all stakeholders involved in the revision process, and outlines COCIR’s respective comments on key matters. It is an updated version of our January 2013 contribution, taking into account new concerns since the European Parliament adopted its position in October 2013.

Our key messages and recommendations are outlined below. Where relevant, the document refers the reader to more detailed COCIR documents that elaborate on the points made.

Summary and COCIR Key Recommendations

1. Definitions and classification rules: Ensure clarity and international convergence, and keep pace with technological innovations (Art. 2, Annex VII)
2. Vigilance reporting: Keep the scope limited to ‘serious’ incidents (Art. 61)
3. Chemicals: Maintain the Commission’s original proposal on the management of hazardous substances (Annex I, Point 7.4)
4. Standards: Maintain the central role of harmonised standards (Art. 6) and use Common Technical Specifications (CTS) only in exceptional cases (Art. 7)
5. Scrutiny procedure: Strengthen Notified Bodies. Minimize and streamline any special review of high risk devices, where truly needed for patient safety (Art. 44)
6. Economic operators: Clarify the various roles and responsibilities and avoid overlaps (Art. 8-12)
7. Transition period: 3 years can only suffice if manufacturers can make meaningful preparations throughout this period, from start to finish (Art. 97)
8. Delegated acts: Maintain legal certainty by limiting the use of delegated acts to cases where they are genuinely needed (Art. 41 and 89)
9. Transparency: Support the Parliament’s proposal to establish a Medical Device Advisory Committee (MDAC) with stakeholders as contributors (Art. 78)
10. Unique Device Identification: Support a single EU system and database that is aligned with the US FDA Final Rule (Chapter 3)
11. Reprocessing: Ensure a high level of patient safety by extending all manufacturer obligations and liabilities to reprocessors (Art. 15)
12. Clinical data and investigations: Tailor the system to the unique characteristics of devices and avoid borrowing from the pharmaceutical model (various)

A detailed briefing of the above points are on the following pages.


1. Definitions and Classification Rules (Art. 2 and Annex VII)

COCIR is concerned by the Parliament’s proposed amendment to the definition of ‘medical device’ (Article 2.1(1)) to include products with ‘indirect’ medical purposes. Taken together with the definition of ‘accessory to a medical device’ (Article 2.1(2)), this risks unjustifiably bringing a great many products, such as general purpose, non-medical software, and consumer electronics like smartphones and tablets, into the scope of the Regulation. More generally, the imprecise nature of the term ‘indirect’ presents the risk of provoking many new disputes about how to regulate borderline products. Many such disputes have taken place in the context of today’s Directive, and the new Regulation should aim to correct, rather than exacerbate, this situation.

Moreover, COCIR believes that device classification rules must evolve alongside technological innovation and progress. The majority of the Annex VII classification rules have been maintained from today’s Directive. Experience in recent years has shown that certain classification rules do not fit well with certain device technologies. There are real-life examples of national competent authorities, Notified Bodies and other actors classifying devices like medical software differently, even though these actors apply the same rules to the same device.

By contrast, COCIR supports the significant efforts made; for the past 20+ years, to harmonise requirements at international level. Definitions of core terms, and classification of devices into risk classes, should therefore match as much as possible the EU’s commitments at international level, particularly within the International Medical Device Regulators Forum (IMDRF). These efforts have included special definitions and classification rules for device categories that do not readily ‘fit’ the traditional rules. COCIR recommends that the Regulation support this principle where justified, and especially in the area of medical software.

COCIR proposal: Oppose Parliament’s amendment of Article 2.1(1). Revise Annex VII to keep pace with technological innovation and international convergence efforts.

2. Vigilance Reporting (Art. 61)

The Commission’s MDR proposal includes a different notion of ‘incident’ and ‘serious incident’ to what exists under the MDD. An ‘incident’ as defined under the MDD is called a ‘serious incident’ under the Commission’s proposal. The events to be reported in both texts have not changed.

The continued reporting by manufacturers of serious incidents (as newly defined) for vigilance purposes is acceptable and proportionate. However, the Parliament has proposed that all events meeting the MDR definition of ‘incident’ be reported in the future. COCIR considers this an extreme and disproportionate expansion of the scope, and estimates that it would result in a many hundredfold increase in the number of manufacturer reports to the electronic system.

The vast majority of these new reports would be routine corrective maintenance calls that are not relevant to patient or user safety. Apart from the significant additional administrative burden that this would impose on manufacturers, it would very likely overload both competent authorities, who must conduct a risk assessment on each event reported, and on Notified Bodies, who must evaluate whether the event reported has an impact on the device’s certificate. Moreover, for higher class devices, there are additional requirements on trend-reporting for the incidents that are non-serious incidents, which would anyhow allow Competent Authorities to react on an increase of frequency or severity of such incidents.

---

1 Article 2(1)(43): ‘incident’ means any malfunction or deterioration in the characteristics or performance of a device made available on the market, any inadequacy in the information supplied by the manufacturer and any unexpected undesirable side-effect.

2 Article 2(1)(44): ‘serious incident’ means any incident that directly or indirectly led, might have led or might lead to any of the following:
   – death of a patient, user or other person,
   – temporary or permanent serious deterioration of the patient’s, user’s or other person’s state of health,
   – serious public health threat.
By keeping such reports limited to serious incidents – as is the case today under the MDD – the information uploaded to the electronic system will remain focused on patient safety and Member States’ post-market surveillance activities.

**COCIR proposal:** Maintain the Commission’s proposed Article 61.

### 3. Chemicals (Annex I, Point 7.4)

The MDD ensured that the use of hazardous substances in medical devices was subject to a risk-benefit analysis, performed by the manufacturer. The Commission’s MDR proposal seeks to strengthen this system, by addressing additional substances such as endocrine disruptors and improving the functioning of Notified Bodies.

The Commission’s proposal is effective for ensuring that medical devices are safe and that hazardous substances are only used in cases where feasible alternatives providing equal benefits for patients are unavailable. Moreover the Commission’s proposal allows for a proper enforcement and verification without overburdening companies, Notified Bodies and the inspection staff of Competent Authorities.

We deem it extremely important that Members States, the Commission and the Parliament be aware and in full agreement that there is no need for additional provisions on chemicals to ensure safety of medical devices.

**COCIR proposal:** Maintain the Commission’s proposed Point 7.4 in Annex I.

### 4. Standards and CTS (Art. 6-7)

A reliable and simple regulation supported by “state of the art” standards covering requirements on safety and performance, which are developed by stakeholders in consensus, is essential to ensure safe and equitable access to healthcare across the European Union. Harmonised standards are – and must remain – the preferred tool to support compliance with the EU regulations.

COCIR considers that the proposed concept of Common Technical Specifications (CTS) should be used only where no relevant harmonised or international standards exist, as it may otherwise lead to contradicting requirements. There shall not be concurrently a harmonized standard and CTS for the same category of medical devices which potentially would bring confusion.

In view of the above, COCIR supports the Parliament’s proposed amendment of Article 7(1). This amendment improves greatly on the Commission’s originally-proposed text, by limiting the range of scenarios in which CTS are justified, by requiring the prior consultation of the MDAC and MDCG, and by obliging the Commission to ensure coherence between any proposed CTS and the European and international standardisation system. However, we note that the Commission’s old language of “or where relevant harmonised standards are not sufficient” is still in the new Article 15(c)(4) and should be removed.

**COCIR proposal:** Support the Parliament’s proposed amendment to Article 7(1), and remove the phrase “or where relevant harmonised standards are not sufficient” from the new Article 15(c)(4).

### 5. Scrutiny (Art. 44)

COCIR supports the strengthening of the existing CE marking system to increase patient safety. In our view, the best way to do this is to raise the standards by which Notified Bodies are designated and supervised, and also raise the levels to which Notified Bodies perform. The Commission’s proposed Articles 32 and 35 go some way towards delivering this, as does the Commission’s September 2013 Implementation Recommendation and Recommendation, which bring forward the 2012 joint plan for immediate action agreed with Member States following the PIP scandal.

---

While COCIR supports the above initiatives, we remain concerned about both the Commission and Parliament proposals for additional pre-market ‘scrutiny’ of certain conformity assessments. We agree that greater controls are warranted for higher risk devices. However the proposals currently offered both add unnecessary delays to market for life-saving devices, and thereby risk seriously undermining patient safety, innovation and competitiveness.

To improve on the current proposals, COCIR suggests a process that operates in parallel to the normal conformity assessment procedure and starts as early as possible. This process should also avoid adding red-tape to the process, without creating new committees or involving the European Medicines Agency, whose competence in the medical devices field would require significant resources to develop. Moreover, we think it essential for existing Notified Bodies to remain involved in the process, in cases where Notified Bodies have demonstrated expertise in the device technology or conformity assessment element in question. Creation of a new category of Notified Bodies, with its own designation and review procedure, must be avoided.

Finally, if the Notified Body determines that special review of the clinical evidence is needed for certain high risk devices, it is sensible for this review to be carried-out by experts that the Member States have vetted up-front for competence and impartiality. However, further to our above concern, this clinical review should start and finish as early on in the device’s pre-market lifecycle as possible, without unduly delaying patient access.

The above proposals are aligned with several industry associations.

**COCIR proposal:** Strengthen Notified Bodies, avoid unnecessary red tape, and keep the pre-market lifecycle lean via a ‘reinforced control procedure’ for the highest risk devices

### 6. Economic Operators (Art. 8-12 and 18)

The roles and responsibilities of all economic operators need to be as clear and distinct as possible. In COCIR’s view, certain of the described tasks overlap and thus add unnecessary administrative burden with no obvious benefit for the patients. In particular, the obligations of importers versus authorised representatives need further clarification.

For imported devices, COCIR considers it counterproductive for the importers’ identification and contact details on the device label. In order to ensure smooth operation of the post-market vigilance system, only the details of the importer’s Authorised Representative in Europe should appear on-pack. Article 11.3 should therefore be deleted.

In addition, the proposal of Parliament (and Council) for the words “medical device” to accompany the CE marking is unnecessary and overly burdensome, as operators would need to translate this term into 20 different languages when labelling their devices.

**COCIR proposals:**

1) Modify Articles 9 and 11 to ensure that regulatory obligations for importers only apply when there is no organisational or legal relation (contract) between the importer and the Authorised Representative.

2) Delete the Article 11.3 obligation for importers to indicate their identification and contact details on the device label

3) Keep Article 18 free of any obligations to accompany the CE marking with the term “medical device”

### 7. Transition Period (Art. 97)

A 3-year transition period is only sufficient for industry if economic operators are able to make full use of this time. For many obligations, it is only possible to start making meaningful preparations after other parts of the Regulation have been implemented, e.g., once a Notified Body has been re-notified, or once a Delegated Act or Implementing Act has been published.

To give but one example, provisions on Unique Device Identification (UDI) are only given in general detail in Chapter III. Much of the detail regarding UDI will only be given at a later date, in the form of a Delegated Act. Either this Delegated Act, or the Regulation itself, will need to specify that the corresponding obligations only apply 3 years after the Delegated Act enters into force.
The Regulation should recognize this reality and specify that the 3-year period starts to be counted only once preparations within companies can meaningfully begin. If this does not happen, operators risk falling out of compliance, or even punished, for factors outside their control. Moreover, in many third countries, device registration is based on EU CE marking. In these markets, it will be necessary to re-register devices due to updated labels, technical files, declarations of conformity and EC certificates.

To correct this problem, **COCIR recommends amendment of the derogations in Article 97(3).** The amended Article should list all provisions for which an implementing measure will be published, and specify that the transition period for those provisions is 3 years after the implementing measure’s date of application.

**COCIR proposal:** Expand the list of derogations in Article 97(3).

**8. Delegated Acts (Art. 41.4 and 89)**

The Commission proposal’s frequent reference to delegated acts creates substantial regulatory uncertainty. COCIR suggests limiting the use of delegated acts to the non-essential elements of the legislative act measures according to Article 290 of the Treaty of Lisbon. COCIR therefore strongly supports the Parliament’s proposals to avoid modification of the General Safety and Performance Requirements (Art. 4.5), the technical documentation rules (Art. 8.2) and the conformity assessment procedures (Art. 42.11) via delegated acts.

However, COCIR remains concerned that the Commission retains the power to amend or supplement the Annex VII classification criteria (Art. 41.4), as this is a key element of the proposed Regulation. It may be justified in special cases to use delegated acts to decide that a device (or category/group thereof) should be classified in another class, by way of derogation from the classification criteria. However, amending or supplementing the classification criteria should only happen through the full EU legislative procedure involving all institutions and stakeholders.

**COCIR proposal:** Amend Articles 41.4 and 89 accordingly.

**9. Transparency (Art. 78)**

COCIR values the establishment of the Medical Device Coordination Group (MDCG) as a group of representatives of EU Member States, supported by the European Commission, tasked to coordinate and harmonise activities amongst EU Member States and contribute to the elaboration of EU guidance. We believe that the currently established Medical Device Expert Group (MDEG) including other stakeholders has proven its value over years. We consider other stakeholders including industry should not be relegated to an observer role but as active contributors.

For this reason, COCIR greatly welcomes the Parliament’s proposal to supplement the MDCG with a Medical Device Advisory Committee (MDAC) that is composed of stakeholders and is actively involved in many aspects of MDR implementation.

**COCIR proposal:** Support the Parliament’s proposed Article 78a.

**10. Unique Device Identification (Chapter III)**

COCIR welcomes the Parliament’s call for a single EU UDI system and database (Article 24.1) and not multiple systems across the EU. We also welcome the Commission’s April 2013 Recommendation, which called for a common EU UDI framework and warned Member States against launching national UDI initiatives in isolation of each other.

To enable true worldwide traceability, the single EU system should be as aligned as possible with the UDI system recently put in place via the United States FDA’s Final Rule. The core UDI features,

---


including the label and the data elements for the EU database, should be as interoperable as possible with what exists in the United States.

Despite the Parliament’s welcome amendment, important details are still missing from the draft Regulation regarding who will administer the single EU system, what the transition times will be for the different device classes, and how many entities the Commission will designate to assign UDIs. If these details cannot be specified in the Regulation, they should be clearly laid out in the forthcoming Delegated Act.

**COCIR proposal:** Support the Parliament’s amendment to Article 24.1, ensure maximum alignment with the FDA Final Rule when implementing the single EU system, and clarify important roles, responsibilities and timelines in either the Regulation or the forthcoming Delegated Act.

11. **Reprocessing (Art. 15)**

To ensure a consistently high level of patient safety, it is appropriate that any reprocessors of medical devices be subject to the same liabilities and obligations incumbent upon devices manufacturers. It would endanger public health and against the MDR’s goal of reducing risk “as far as possible” to adopt alternative approaches such as treating devices as reusable by default, or excusing reproprocessors from obligations linked to the conformity assessment procedure. Devices should not be reprocessed if the suitability of reprocessing has not been rigorously demonstrated, and any reprocessing that takes place should be subject to the same level of regulatory controls as newly-manufactured devices.

**COCIR proposal:** Maintain the Commission’s proposed Article 15.

12. **Clinical Data and Investigations (various Articles)**

COCIR firmly believes that clinical investigations for medical devices are fundamentally different from clinical trials conducted in the pharmaceuticals world. As such, we are concerned about various proposals, from all 3 EU institutions, that seem to incoherently borrow ideas from the recent review of the Clinical Trials Directive 2001/20/EC and they do not readily fit with the concepts set out in EN ISO 14155 on good clinical practice.

We are particularly concerned about the Parliament’s proposal for mandatory submission of clinical investigation results to an electronic system that will be made partially available to the public (Article 57.3). Full clinical investigation reports should only be accessible to professionals who are qualified to understand them, and commercially-sensitive information potentially present in these reports must be protected whenever access is granted to the electronic system.

**COCIR proposal:** Devise clinical requirements that are tailored to the unique characteristics of medical technology, and protect commercially-sensitive information.